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Background/aims: To investigate the prevalence of erectile dysfunction (ED) in patients with
coronary artery disease (CAD), its relationship between the severity of ED and the extent of
coronary vessel involvement and to register the mean time interval between them.
Methods: 240 patients with CAD divided into three age-matched groups: Group 1 (n ¼ 60),
ACS with one-vessel disease (1VD); group 2 (n ¼ 60), ACS with 2,3VD; group 3 (n ¼ 60), CSA.
Control group (C, n ¼ 60) was composed of patients with suspected CAD who were found to
have entirely normal coronary arteries by angiography. ED as any value <26 according to
the Gensini’s scores and according to the International Index of Erectile Function (IIEF).
Results: ED prevalence was 76%. ED prevalence was lower in G1 vs. G3 (22 vs.65%). G2 ED
rate [55%, P < 0.0001] IIEF ¼ 24 (17e29) & Gensini’s scores-21 (12.5e32) were significantly
different from G1 and similar to G3, ED in ACS differs according to the extent of CAD. G3
patients who had ED symptoms prior to CAD symptoms and time interval between ED and
CAD symptom onset in CCS according to number of vessels. Onset of sexual dysfunction
occurred before CAD onset with a mean time interval of 24 m [12e36].
Conclusion: Early diagnosis of ED, cardiovascular assessment and aggressive treatment of
cardiovascular risk factors might have contributed to prevent the acute events of this
patient. Patients should be systematically screened for ED as a part of periodic examination
programs. This would lead to early detection of modifiable vascular risk factors, or already
existing vascular disease and to prevent ED and vascular disease progression through
pharmacological and life style modifications.
Copyright ª 2013, Cardiological Society of India. All rights reserved.
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T1. Introduction between the ages of 40 and 60 years.2,3 The severity of ED is
EErectile dysfunction (ED) is defined as the consistent inability
to reach and maintain an erection satisfactory for sexual ac-
tivity.1 This condition is reported to affect 42% of the adultsR(mobile).
A. Sai Ravi Shanker).
2013, Cardiological Socieclassified as mild to severe, according to the International
Index of Erectile Function.4 Organic ED (i.e. one with an un-
derlying physical etiology) and coronary artery disease (CAD)
are closely linked, as they are both consequences ofty of India. All rights reserved.
Ai n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 8 0e1 8 6 181endothelial dysfunction, leading to restrictions in blood
flow.5,6 Prevalence of ED as high as 75% has been reported in
the established CAD patients.7e12
Atherosclerosis can play a major role in the development
of ED both in the general population and in diabetic
patients.13e17 In the diabetic population, the prevalence of
silent CAD is particularly high.18,19
Evidence to support ED as a predictor of CAD is:
 A significant proportion of men with ED exhibit early signs
of CAD.
 Men with pre-existing ED may develop more severe CAD
than those without ED.
 The interval between the onset of ED symptoms and the
occurrence of CAD symptoms is estimated at 2e3 years and
a cardiovascular event at 3e5 years.
 There is a common endothelial pathology underlying both
ED and CAD.
 Erectile dysfunction is associated with increased all-cause
mortality primarily through its association with CAD
mortality.
Erectile dysfunction is associated with significant changes
in established cardiovascular risk factors such as fasting
lipids, fasting glucose, body mass index (BMI), C-reactive
protein (CRP) and homocysteine.20e23 Men with ED generally
exhibitmore severe CAD and left ventricular dysfunction than
those without ED,24e26 and the severity of ED may also be
correlated with the severity of CAD.27 It should be noted,
however, that penile Doppler testing cannot be reliably used
to identify at-risk men because of its average sensitivity and
specificity, low positive predictive value and high negative
predictive value.28 In around two-thirds of men, the onset of
CAD is preceded by ED (Montorsi et al.). A number of studies
have estimated the interval between the onset of ED symp-
toms and the occurrence of CAD symptoms as 2e3 years and a
cardiovascular event [myocardial infarction (MI) or stroke] as
3e5 years,29,30 although longer time frames have been
reported.31
Using Framingham risk scores, the relative risk of devel-
oping CAD within 10 years in men with moderate-severe ED
has been estimated as 4.9% in those aged 30e39 years,
increasing to 21.1% in those aged 60e69 years.32 This com-
pares with 4.3% and 16.6% inmenwithout ED for the same age
groups, i.e. an increase in relative risk of 1.14 and 1.27
respectively. The risk of experiencing a cardiovascular event
within a 10-year timeframe is increased by 1.3e1.6 times in
men with ED vs. men without ED.33,34
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E2. Aims and objectives of the study
To investigate the prevalence of ED in patients with CAD and
to evaluate the relationship between the severity of ED and
the extent of coronary vessel involvement and to register the
first symptom and the mean time interval between them.
We tested the hypothesis that ED prevalence is related to
coronary atherosclerotic burden that in turn is related to the
type of clinical presentationdacute coronary syndrome (ACS)
vs. chronic coronary syndrome (CCS). As atherosclerosis is a
R
systemic disorder, penile circulation might be involved to a
similarly different extent as coronary circulation in ACS vs.
CCS patients. If true, ED prevalence should be low in the
former and high in the latter.35,363. Methods
180 patients with CAD divided into three age-matched groups:
Group 1 (G1, n ¼ 60), ACS with one-vessel disease (1-VD);
Group 2 (G2, n ¼ 60), ACS with 2, 3-VD; Group 3 (G3, n ¼ 60),
chronic stable angina, alongwith Control group (C, n¼ 60) was
composed of patients with suspected CAD who were found to
have entirely normal coronary arteries by angiography.
International Index of Erectile Function (IIEF) question-
naires were used to assess extent of ED. ED as any value <26
according to the Gensini’s scores and according to the IIEF.
Between Dec 2010 and Nov 2011, 1630 patients underwent
coronary angiography for both ACS and CCS syndromes at
Narayana medical college and Superspeciality hospital,
Nellore, Andhra Pradesh. Two-hundred and two patients
(12.4%) were found to have angiographically normal coronary
arteries. Five-hundred and seventy (35%) were classified as
ACS (i.e. first episode of acute ST-elevation myocardial
infarction or non-ST elevation myocardial infarction or un-
stable angina),37 whereas the remaining patients were clas-
sified as CCS (defined as clinical and non-invasive evidence of
stable myocardial ischemia lasting >2 months).
We have excluded:
1. Patients with previous percutaneous or surgical myocardial
revascularization procedures.
2. Patients with diseases that could alter sexual activity, such
as liver cirrhosis, renal failure, thyroid disease (hypo- and
hyperthyroidism on replacement treatment), major
depression on long-term pharmacological treatment, and
spinal cord injuries, and those with previous pelvic, penile,
urethral, or prostate trauma or surgery.
3. Patients with primary erectile dysfunction were excluded.
All patients underwent complete routine laboratory tests,
included lipid profile, fasting glucose, and total and free-
plasma testosterone levels. Diagnostic coronary angiography
was carried out in all patients by the standard technique. If
required, percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft surgery was carried out
during the hospital stay. Risk factors (when not previously
known) were defined according to the ESC/ACC/AHA guide-
lines as follows38 hypertension as blood pressure >140/
90 mmHg in three consecutive readings, at rest; hypercho-
lesterolemia as total cholesterol level >200 mg/dL and/or LDL
cholesterol level >130 mg/dL, diabetes as fasting glucose level
>126 mg/dL; obesity as body mass index (BMI) >30 kg/m2; and
family history of CAD as parents with CAD at age <55 (father)
or <65 (mother).
Ankle-brachial index was taken as an accurate and reliable
marker of generalized atherosclerosis. It was calculated by
dividing the ankle systolic pressure by the brachial pressure
(bothmeasurements taken by cuff manometers). The lower of
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Fig. 1 e Schematic drawing of the GENSINI score (left). The
method assigns a different severity score depending on the
degree of stenosis, its location (proximal, middle or distal
tract) along the target vessel and the type of coronary
vessel involved (left anterior descending, left CX or RCA).
An example of Gensini score calculation is shown on the
right part of the figure. MLCA, main left coronary artery;
LAD, left anterior descending; CFx, left circumflex; RCA,
right coronary artery.A
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i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1 8 0e1 8 6182the indexes obtained for the two legs was used as themeasure
of disease severity.42
The Narayana medical college ethics committee approved
the study protocol and each patient gave written informed
consent.
IIEF-EFD questionnaire for ED (questions 1e5 and 15)
(1) Q: how oftenwere you able to get an erection during sexual
activity? A: no sexual activity (0), almost never/never (1), a
few times (much less than half of the time) (2), sometimes
(about half of the time) (3), most times (much more than
half the time) (4), almost always/always (5).
(2) Q: when you had an erection with sexual stimulation, how
often were your erections hard enough for penetration? A:
no sexual activity (0), almost never/never (1), a few times
(much less than half of the time) (2), sometimes (about half
of the time) (3), most times (muchmore than half the time)
(4), almost always/always (5).
(3) Q: when you attempted sexual intercourse, how often
were you able to penetrate your partner? A: no sexual ac-
tivity (0), almost never/never (1), a few times (2), some-
times (about half of the time) (3), most times (much more
than half the time) (4), almost always/always (5).
(4) Q: during sexual intercourse, how difficult was it to
maintain your erection after you had penetrate your
partner? A: no sexual activity (0), almost never/never (1), a
few times (2), sometimes (about half of the time) (3), most
times (much more than half the time) (4), almost always/
always (5).
(5) Q: during sexual intercourse, how difficult was it to
maintain your erection to completion of intercourse? A:
did not attempt intercourse (0), extremely difficult (1), very
difficult (2), difficult (3), slightly difficult (4), not difficult (5).
(6) Q: how do you rate your confidence that you could get and
keep an erection? A: very low (1), low (2), moderate (3), high
(4), very high (5)
3.1. Quantitative coronary angiography
Coronary angiography analysis was performed by the
cardiologist who is unaware of the patient’s ED. IIEF-EFD
questionnaire, using ARTREK Quantum IC (Image Comm.
System Inc, Sunnyvale, CA, USA).39 The outer diameter of
the contrast-filled catheter was used for calibration. The le-
sions were analyzed in multiple projections, and reference
vessel diameter, minimal lumen diameter, and percent
diameter stenosis were measured from the ‘worst’ angio-
graphic view. Significant angiographic narrowing was
defined as >50% diameter stenosis involving either one
major epicardial vessel at any site or any collaterals with
>0.3 mm diameter. Patients were classified as having 1-VD,
2-VD, or 3-VD, if they had a single lesion in 1, 2, or 3 coronary
vessels.
3.2. Gensini’s score
The method assigns a different severity score depending on
the degree of stenosis, its location (proximal, middle or distal
tract) along the target vessel and the type of coronary vessel
involved (LAD, LCX or RCA) (Fig. 1).40
R
E
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Erectile function was evaluated by IIEF-EFD, a validated
15-item self-administered questionnaire.41 Erectile function is
specifically addressed by six questions that form the so called
‘erectile function domain’ of the questionnaire. Each question
is scored 0 to 5. ED is defined as any value <26. In the case of
ED, patient was asked to answer the following question: ‘Did
ED symptoms come before CAD symptoms?’ If yes,‘how long
before? (Months)’. IIEF questionnaire was administered to
patients after a mean time interval of 3 [2e5] days since the
admission to the hospital.3.4. Statistical analysis
The relationship among ED prevalence, clinical presentation,
and extension of CAD was analyzed by multivariable logistic
regression adjusting for the following covariates: age; dia-
betes; hypertension; hypercholesterolemia; family history of
CAD; smoking; BMI. Adjusted odds ratios (OR) and 95% CI were
estimated. The area under the ROC curve was used as a
measure of prediction ability. Data are presented as
Table 1 e Baseline characteristics with risk factors.
Control (n ¼ 60) Gr-I (n ¼ 60) Gr-II (n ¼ 60) Gr-III (n ¼ 60) p value
Age (years) 48.5  9 52  8.4 53  8.3 55.4  5.7 0.21
BMI (kg/m2) 26.7  1.2 26.9  1.3 26.4  1.3 26.9  2.1 0.86
Symptom onset (months) 28  12 22  13 18  12 16  9 0.008
Risk factors
Hypertension 57% 56% 54% 55% 0.13
Diabetes 15% 16% 32% 38% 0.06
Hypercholesterolemia 61% 78% 76% 84% 0.06
Smoking 28% 45% 52% 58% 0.08
Obesity 12% 15% 21% 18% 0.07
F/H of CAD 6% 28% 38% 29% 0.005
>3 Risk factor 26% 42% 48% 52% 0.52
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 8 0e1 8 6 183mean þ SD, unless otherwise stated. A two tailed P-value
<0.05 was considered as significant.A
4. Results
One hundred and eighty patients with angiographically
documented CAD were registered. Clinical characteristics of
study population are reported in (Table 1). There was no
difference in age between groups. Risk factors were uni-
formly distributed between groups, except for smoking and
diabetes that were significantly more frequent in G2 and G3
when compared with G1, respectively. Noteworthy, almost
50% of patients in each group had >3 risk factors. Overall ED
prevalence was 47%. When separately considered, ED prev-
alence was 24%, 56%, and 64% in G1, G2, and G3, respectively
(p < 0.0001 for G1 vs. G2 and G1 vs. G3; p < 0.45 for G2 vs. G3).
ED prevalence in Controls was 22%. ED prevalence was lower
in G1 vs. G3 (24 vs. 64%, p<0.00001) as a result of less
atherosclerotic burden as expressed by Gensini’s score [2 vs.
40, p<0.0001] Controls had ED rate values similar to G1 (24%)
(Table 2). Corresponding IIEF-EFD scores were (median and
inter quartile range): 26 (24e28), 24 (18e29), and 27 (26e29) in
G1, G2, and G3, respectively (p < 0.0004 for G1 vs. G2,
P < 0.0001 for G1 vs. G3, and p¼0.48 G2 vs. G3) and 23 (20e26)
in controls.
Extent of coronary atherosclerosis as assessed by modified
Gensini’s score was significantly different within each group
and between each group and controls. Systemic atheroscle-
rosis, as reflected by the ankle-brachial index, was greater in
TRTable 2 e Clinical characteristics of study population.
Control (n ¼ 60) Gr-I (n ¼
STEMI e 64%
NSTEMI e 16%
USA e 20%
CSA e
ED prevalence 22% 24%
Involved coronary vessels, (n) 0 1  0
IIEF-EFD score 23 (20e26) 26 (24e
Modified Gensini’s score 0 (0e2) 4 (0e8)
Time interval 12 (9e24) 14 (9e2
Brachial-ankle index 1.12  0.1 0.92 
R
EG3 when compared with G1 (0.80  0.3) vs. 092  0.10,
p<0.0001. Severe ED (a score<10) was present in 35/135 (26%)
of the CAD patient population and was significantly more
frequent in 2, 3-VD when compared with 1-VD (31 vs. 12.5%,
p<0.01).
Erectile dysfunction prevalence and IIEF-EFD score ac-
cording to the extent of coronary atherosclerosis. IIEF-EFD
score was significantly lower in multi-vessel disease when
compared with single-vessel disease [18 (11.5e23) vs. 21
(16e24), p¼0.006]. An inverse relationship was found between
modified Gensini’s score and IIEF score: R ¼ 20.312, p<0.0001.
In G3 patients who complained of ED, symptoms appeared
prior to CAD detection in 58/62 (93%) of cases, with a mean
time interval of 24 (12e36) months (Fig. 2) Time intervals in 1-,
2-, 3-VD patients were 14 months (9e24), 24 months (16e32),
and 33 months (21e47), respectively. There was a significant
relationship between length of time interval between ED and
CAD onset and the number of vessel involved after adjusting
for the same covariates as for logistic regression (p¼0.016).
Age, multi-vessel coronary involvement, and CCS as clinical
presentation were independent predictors of ED. Conversely,
in patients with ACS (G1 and G2), we used the number of
coronary vessels involved as the dependent variable and ED
as a predictor. The presence of ED was associated with a four-
fold increase in the risk of having 2- or 3-VD vs.1-VD (Table 3).
Sensitivity, specificity, and positive and negative predictive
values of ED vs. multi-vessel disease were 55% (95% CI:
0.35e0.55), 78% (95% CI: 0.68e0.85), 71% (95% CI: 0.59e0.81),
and 63% (95% CI: 0.53e0.71), respectively. The area under the
ROC curve was 0.663 (95% CI: 0.596e0.725).
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D60) Gr-II (n ¼ 60) Gr-III (n ¼ 60) p value
68% e 0.48
15% e 0.52
17% e 0.12
100%
56% 64% <0.001
2.2  0.5 2.4  0.8
28) 24 (18e29) 27 (26e29) <0.001
22 (14e32) 42 (20e68) <0.001
4) 24 (16e32) 34 (21e47) 0.016
0.1 0.90  0.1 0.80  0.3 0.001
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Fig. 2 e Prevalence of ED in the four groups of patients. ACS CSA
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Fig. 3 e Prevalence of ED in the ACS and CSA groups.
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A significant proportion of men with ED exhibit early signs of
CAD, and this group may develop more severe CAD than men
without ED. Prevalence of ED differs across subsets of patients
with CAD and is related to extent of CAD. In group I, ED
prevalencewas 24%. This valuewas similar to that obtained in
age-matched controls with normal coronary arteries.15 Thus,
most patients with ACS and 1-VD do not complain of ED as
result of an overall low coronary and penile atherosclerotic
burden.
The finding that patients with CCS and 1-VD had higher ED
rate (65 vs. 22%, p< 0.0001) when comparedwith patientswith
ACS and 1-VD, confirms the role of different pathophysiolog-
ical background and related atherosclerotic burden at work in
CCS (Fig. 3). Infact, multivariate analysis showed that patients
with CCS presentation had a 2.3-fold increase in relative risk
of ED when compared with those with ACS, independently of
other conventional risk factors. The lower ankle-brachial
index (0.98 þ 0.10 vs.0.80  0.28, p < 0.0001), an accurate and
reliable marker of generalized atherosclerosis, supported a
more advanced vascular involvement in CCS. The time in-
terval between the onset of ED symptoms and the occurrence
of CAD symptoms and cardiovascular events is estimated at
2e3 years and 3e5 years, respectively; this interval allows for
risk factor reduction.
According to this finding, we evaluated whether ED may
predict coronary artery involvement in ACS. Interestingly
enough, this suggests that the IIEF questionnaire may be a
useful ‘bedside’ test to predict the extension of CAD in ACS:
according to positive predictive value seven out of 10 patients
with ED turned out to have angiographic multivessel disease.
ED-coronary atherosclerosis’ relationship by assessing ED
rate according to CAD extension is being evaluated in this
E
TRTable 3 e ED prevalence.
ACS CCS
1 VD 2 VD 3VD 1VD 2VD 3VD
ED prevalence (%) 22 52 58 65 62.5 66
R
study. Interesting enough, having 2- or 3-VD did not signifi-
cantly increased ED prevalence as compared to 1-VD in both
ACS and CCS patients with similar age (Fig. 2) suggesting ED as
a sort of ‘on-off’ phenomenon that we hypothesized takes
place when 0.50% angiographic obstruction of at least one
major coronary vessel occurs. If true, having 2- or 3-VD would
not add to ED prevalence. Almost 30% of patients with proved
CAD did not complain of ED. Age may be an explanation. We
found age to be independent predictor of ED in the whole
study patient population, with a 10% per patient increase in
the yearly relative risk of ED. ED significantly increased over
time being 30% under 50 years and close to 100% over 60 years
of age. At any age ED rate was similar regardless extent of
CAD, confirming the ‘on-off’ phenomenon.
We found that severe ED (a score<10) wasmore frequent in
patients with multi-vessel as compared to single-vessel dis-
ease (31 vs. 12.5%, p < 0.01). Moreover, IIEF-EFD score was
significantly lower in the former than in the latter group and
significant inverse relationship between IIEF-EFD and modi-
fied Gensini’s score were found indicating more severe ED in
patients with more diffuse coronary artery involvement.
Thus, severe ED in patients with stable CAD should raise
questions about multi-vessel coronary involvement.
C
TE6. Conclusion
In the present study, ED prevalence was 24%. ED rate of con-
trol groupwas similar to that found in general populationwith
no heart disease. Patients with CCS presentation had a 2.3-
fold increase in relative risk of ED when compared with
those with ACS. This suggests that the IIEF questionnaire may
be a useful ‘bedside’ test to predict the extension of CAD. Se-
vere ED (a score<10) was more frequent in patients with
multi-vessel as compared to single-vessel disease 0.83% of
patients with CCS reported ED symptoms before angina pec-
toris onset, with a mean interval of 22 months heart disease.
The key findings of this study are (1) ED rate significantly
differs across patients with established CAD according to
coronary clinical presentation and atherosclerosis burden: it
is low in ACS and 1-VD and high in CCS. (2) ED severity but not
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 8 0e1 8 6 185ED prevalence is related to extent of CAD. (3) ED symptoms
come prior to CAD symptoms in virtually all patients with a
mean time-interval of 3 years. (4) All men with ED should
undergo a thorough medical assessment, including testos-
terone, fasting lipids, fasting glucose and blood pressure
measurement. (5) Following assessment, patients should be
stratified according to the risk of future cardiovascular events.
(6) Those at high risk of cardiovascular disease should be
evaluated by stress testing with selective use of computed
tomography (CT) or coronary angiography. (7) Improvement in
cardiovascular risk factors such as weight loss and increased
physical activity has been reported to improve erectile func-
tion. (8) In men with ED, hypertension, diabetes and hyper-
lipidemia should be treated aggressively, bearing in mind the
potential side effects. (9) Management of ED is secondary to
stabilizing cardiovascular function, and controlling cardio-
vascular symptoms and exercise tolerance should be estab-
lished prior to initiation of ED therapy. (10) Clinical evidence
supports the use of phosphodiesterase 5 (PDE5) inhibitors as
first-line therapy inmenwith CAD and comorbid ED and those
with diabetes and ED. (11) Review of cardiovascular status and
response to ED therapy should be performed at regular
intervals.Conflicts of interest
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